This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

John D. Hamilton, MD; Pamela M. Hartigan, PhD; Michael S. Simberkoff, MD
The AIDS Cooperative Studies Group US Department of Veterans Affairs Durham, NC

JAMA. 1992;267(18):2472-2473.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The recent articles by Lagakos et al¹ and Easterbrook et al² provide data on the effects of zidovudine on black and Hispanic human immunodeficiency virus (HIV)-infected patients. Neither study, however, was originally designed to assess these subgroups of patients prospectively. Both articles were prompted by reports from the US Department of Veterans Affairs (VA) Cooperative Study 298—first to the Food and Drug Administration Antiviral Advisory Committee in February 1991 and then in abstract form³—suggesting that minority patients may respond differently to zidovudine than white patients do.

Lagakos et al combined data from two studies by the AIDS [acquired immunodeficiency syndrome] Clinical Trials Group (ACTG), which were designed to evaluate the efficacy of zidovudine vs placebo in symptomatic (ACTG trial 016) and asymptomatic (ACTG trial 019) HIV infection. Subset analyses showed that zidovudine was equally effective in delaying the onset of AIDS in black, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?